Integra LifeSciences (NASDAQ:IART) Trading Down 3.7% – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) was down 3.7% on Thursday . The stock traded as low as $15.53 and last traded at $15.46. Approximately 124,721 shares traded hands during trading, a decline of 86% from the average session volume of 873,826 shares. The stock had previously closed at $16.06.

Wall Street Analysts Forecast Growth

IART has been the subject of several research reports. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Thursday, June 18th. BMO Capital Markets assumed coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Truist Financial upped their price target on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Finally, Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Stock Performance

The stock’s 50-day simple moving average is $17.48 and its 200 day simple moving average is $14.71. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The company has a market capitalization of $1.21 billion, a PE ratio of -172.65, a P/E/G ratio of 0.81 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Paradigm Capital Management Inc. NY purchased a new stake in Integra LifeSciences in the second quarter valued at $61,766,000. Wellington Management Group LLP boosted its stake in shares of Integra LifeSciences by 12.4% in the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after buying an additional 160,814 shares in the last quarter. Systematic Financial Management LP boosted its holdings in Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after buying an additional 48,094 shares in the last quarter. Bank of America Corp DE increased its stake in Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after purchasing an additional 589,408 shares in the last quarter. Finally, Invenomic Capital Management LP boosted its position in shares of Integra LifeSciences by 78.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after buying an additional 463,729 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.